CN1633281A - 口内崩解的伐地考昔组合物 - Google Patents

口内崩解的伐地考昔组合物 Download PDF

Info

Publication number
CN1633281A
CN1633281A CNA028211413A CN02821141A CN1633281A CN 1633281 A CN1633281 A CN 1633281A CN A028211413 A CNA028211413 A CN A028211413A CN 02821141 A CN02821141 A CN 02821141A CN 1633281 A CN1633281 A CN 1633281A
Authority
CN
China
Prior art keywords
valdecoxib
composition
pharmaceutically acceptable
dissolution
tablet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028211413A
Other languages
English (en)
Chinese (zh)
Inventor
特兰·T·李
布莱克·C·路德维格
约瑟夫·P·里奥
尤迪·J·沙
山本健
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PharMetrix Corp
Original Assignee
PharMetrix Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PharMetrix Corp filed Critical PharMetrix Corp
Publication of CN1633281A publication Critical patent/CN1633281A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA028211413A 2001-09-26 2002-09-23 口内崩解的伐地考昔组合物 Pending CN1633281A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32535601P 2001-09-26 2001-09-26
US60/325,356 2001-09-26

Publications (1)

Publication Number Publication Date
CN1633281A true CN1633281A (zh) 2005-06-29

Family

ID=23267542

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA028211413A Pending CN1633281A (zh) 2001-09-26 2002-09-23 口内崩解的伐地考昔组合物
CNA028189078A Pending CN1703203A (zh) 2001-09-26 2002-09-23 感官可接受的口腔内崩解组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA028189078A Pending CN1703203A (zh) 2001-09-26 2002-09-23 感官可接受的口腔内崩解组合物

Country Status (25)

Country Link
US (1) US20030181501A1 (enExample)
EP (2) EP1429736A2 (enExample)
JP (2) JP2005512964A (enExample)
KR (2) KR20040058189A (enExample)
CN (2) CN1633281A (enExample)
AP (2) AP2004002999A0 (enExample)
AR (1) AR037239A1 (enExample)
BR (2) BR0212778A (enExample)
CA (2) CA2461044A1 (enExample)
CO (2) CO5570684A2 (enExample)
EA (2) EA200400357A1 (enExample)
EC (1) ECSP045029A (enExample)
GE (1) GEP20063856B (enExample)
HK (1) HK1079988A1 (enExample)
IL (2) IL160855A0 (enExample)
IS (2) IS7178A (enExample)
MA (2) MA27682A1 (enExample)
MX (2) MXPA04002652A (enExample)
NO (2) NO20041258L (enExample)
OA (2) OA12707A (enExample)
PL (2) PL369298A1 (enExample)
TN (2) TNSN04045A1 (enExample)
WO (2) WO2003026623A1 (enExample)
YU (1) YU34804A (enExample)
ZA (2) ZA200401953B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103919742B (zh) * 2008-11-25 2017-04-12 田边三菱制药株式会社 口腔速崩片及其制备方法

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005002557A1 (en) * 2003-07-03 2005-01-13 Warner-Lambert Company Llc Pharmaceutical compositions including an ether and selective cox-2 inhibitor and uses thereof
US20050186271A1 (en) * 2004-02-24 2005-08-25 Sheskey Paul J. Process for dispersing a fluid in a mass of solid particles
JP5551852B2 (ja) * 2004-08-10 2014-07-16 味の素株式会社 苦味の低減したナテグリニド含有製剤
EP1839650A1 (en) * 2004-12-28 2007-10-03 Eisai R&D Management Co., Ltd. Quick disintegration tablet and method of producing the same
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US20100015221A1 (en) * 2005-12-20 2010-01-21 Eisai R&D Management Co.Ltd. Orally rapid disintegrating tablet preparation comprising fat-soluble active ingredients
US8535714B2 (en) 2006-01-06 2013-09-17 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8202535B2 (en) 2006-01-06 2012-06-19 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage forms
US8865743B2 (en) * 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8252329B2 (en) 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
WO2007087188A2 (en) * 2006-01-20 2007-08-02 Merck & Co., Inc. Taste-masked tablets and granules
US20070196494A1 (en) * 2006-02-17 2007-08-23 Arnaud Grenier Low-friability, patient-friendly orally disintegrating formulations
CA2687124A1 (en) * 2006-05-19 2007-12-13 Somaxon Pharmaceuticals, Inc. Low dose doxepin formulations, including buccal, sublingual and fastmelt formulations, and uses of the same to treat insomnia
JP5420535B2 (ja) * 2007-06-06 2014-02-19 ビーエーエスエフ ソシエタス・ヨーロピア 速崩性錠剤製造のための医薬製剤
US8568780B2 (en) * 2007-06-06 2013-10-29 Basf Se Pharmaceutical formulation for the production of rapidly disintegrating tablets
JP2010529073A (ja) * 2007-06-06 2010-08-26 ビーエーエスエフ ソシエタス・ヨーロピア チュアブル錠及びトローチ剤製造のための医薬製剤
WO2008148742A2 (de) * 2007-06-06 2008-12-11 Basf Se Pharmazeutische formulierung für die herstellung von schnell zerfallenden tabletten
KR101606944B1 (ko) * 2007-08-07 2016-03-28 아셀알엑스 파마슈티컬스 인코퍼레이티드 경구 경점막 투여형을 사용한 시술시 진정과 무통을 위한 조성물 및 방법
EP2268268A2 (en) * 2008-03-24 2011-01-05 Wockhardt Research Centre Orally disintegrating compositions of rhein or diacerein
US8945592B2 (en) * 2008-11-21 2015-02-03 Acelrx Pharmaceuticals, Inc. Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
WO2010144865A2 (en) 2009-06-12 2010-12-16 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
US20110091544A1 (en) * 2009-10-16 2011-04-21 Acelrx Pharmaceuticals, Inc. Compositions and Methods for Mild Sedation, Anxiolysis and Analgesia in the Procedural Setting
FR2968995B1 (fr) * 2010-12-16 2013-03-22 Sanofi Aventis Composition pharmaceutioue pour une administration par voie orale destinee a eviter le mesusage
CN106822007B (zh) 2015-09-11 2021-12-31 西姆莱斯股份公司 口服制剂

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5576014A (en) * 1994-01-31 1996-11-19 Yamanouchi Pharmaceutical Co., Ltd Intrabuccally dissolving compressed moldings and production process thereof
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
SK74396A3 (en) * 1995-06-13 1997-04-09 American Home Prod Organoleptically acceptable oral pharmaceutical compositions
JPH11513641A (ja) * 1995-10-20 1999-11-24 ファルマシア・アンド・アップジョン・カンパニー ブリスターパッケージ
KR100373622B1 (ko) * 1996-05-17 2003-07-12 머크 앤드 캄파니 인코포레이티드 사이클로옥시게나제-2로매개된질환의1일1회치료용조성물
EP0863134A1 (en) * 1997-03-07 1998-09-09 Merck Frosst Canada Inc. 2-(3,5-difluorophenyl)-3-(4-(methyl-sulfonyl)phenyl)-2-cyclopenten-1-one useful as an inhibitor of cyclooxygenase-2
US6465009B1 (en) * 1998-03-18 2002-10-15 Yamanouchi Pharmaceutical Co., Ltd. Water soluble polymer-based rapidly dissolving tablets and production processes thereof
CN1679556A (zh) * 1999-12-08 2005-10-12 法马西亚公司 维得克西组合物
US6316029B1 (en) * 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
US6800297B2 (en) * 2000-06-15 2004-10-05 Acusphere, Inc. Porous COX-2 inhibitor matrices and methods of manufacture thereof
PT1309315E (pt) * 2000-08-18 2006-09-29 Pharmacia Corp Formulacao oral de desintegracao rapida de valdecoxib
CN1638739A (zh) * 2000-08-18 2005-07-13 法玛西雅厄普约翰美国公司 治疗成瘾性障碍的化合物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103919742B (zh) * 2008-11-25 2017-04-12 田边三菱制药株式会社 口腔速崩片及其制备方法

Also Published As

Publication number Publication date
CO5570659A2 (es) 2005-10-31
MXPA04002798A (es) 2004-07-05
ZA200402364B (en) 2005-01-13
ECSP045029A (es) 2004-04-28
GEP20063856B (en) 2006-06-26
IS7177A (is) 2004-03-11
TNSN04047A1 (fr) 2006-06-01
AP2004002999A0 (en) 2004-03-31
OA12707A (en) 2006-06-26
CA2461630A1 (en) 2003-04-03
HK1079988A1 (zh) 2006-04-21
IL160848A0 (en) 2004-08-31
EA200400357A1 (ru) 2004-08-26
MA27682A1 (fr) 2006-01-02
CO5570684A2 (es) 2005-10-31
NO20041258L (no) 2003-03-27
WO2003026697A3 (en) 2003-07-03
EP1490035A1 (en) 2004-12-29
MXPA04002652A (es) 2004-06-07
KR20040058189A (ko) 2004-07-03
AP2004002998A0 (en) 2004-03-31
NO20041532L (no) 2004-04-15
YU34804A (sh) 2006-08-17
EA200400352A1 (ru) 2004-12-30
OA13060A (en) 2006-11-10
AR037239A1 (es) 2004-11-03
WO2003026697A2 (en) 2003-04-03
JP2005506987A (ja) 2005-03-10
CA2461044A1 (en) 2003-04-03
WO2003026623A8 (en) 2004-09-30
MA27542A1 (fr) 2005-10-03
JP2005512964A (ja) 2005-05-12
IL160855A0 (en) 2004-08-31
PL369298A1 (en) 2005-04-18
PL369297A1 (en) 2005-04-18
KR20040044990A (ko) 2004-05-31
CN1703203A (zh) 2005-11-30
EP1429736A2 (en) 2004-06-23
BR0212778A (pt) 2004-12-07
ZA200401953B (en) 2005-05-09
BR0212861A (pt) 2004-10-05
IS7178A (is) 2004-03-11
WO2003026623A1 (en) 2003-04-03
TNSN04045A1 (fr) 2006-06-01
US20030181501A1 (en) 2003-09-25

Similar Documents

Publication Publication Date Title
CN1633281A (zh) 口内崩解的伐地考昔组合物
KR100645866B1 (ko) 발데콕시브 조성물
JP5296456B2 (ja) 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠
CN1376146A (zh) 提高了生物利用率的雪列柯西的固态形式
CN1592622A (zh) 含有fexofenadine的口溶性片剂
CN1638803A (zh) 口腔内速崩解性片剂
CN1913876A (zh) 含药物的颗粒和包含这种颗粒的固体制剂
JP2015535289A5 (enExample)
US20120276199A1 (en) Taste masked pharmaceutical formulations
WO2011019043A1 (ja) ２種以上の粒子を含有する口腔内速崩壊錠
CN1031183A (zh) 二氢吡啶贮存制剂
TW201442712A (zh) 有機化合物之調配物
TWI418370B (zh) 溶出安定性製劑
EP2589376B1 (en) Oral disintegrating composition of anti-histamine agents
FR2999937A1 (fr) Unite solide a haute teneur en fexofenadine et son procede de preparation
TWI651085B (zh) Ｎ－［５－［２－（３，５－二甲氧基苯基）乙基］－２ｈ－吡唑－３－基］－４－［（３ｒ，５ｓ）－３，５－二甲基哌－１－基］苯甲醯胺之醫藥調配物
JP6151413B2 (ja) 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠
HK1071294A (en) Intraorally disintegrating valdecoxib compositions prepared by spray drying process
JP2005512990A5 (enExample)
JP2005508348A (ja) 噴霧乾燥法により製造された口内で崩壊するバルデコキシブ組成物
JP2005512990A (ja) 流動層造粒法により製造される口腔内崩壊型バルデコキシブ組成物
HK1050200A (en) Solid-state form of celecoxib having enhanced bioavailability
HK1103968A (en) A medicament-containing particle and a solid preparation containing the particle
JP2004091373A (ja) 分解に対する安定性及び含量均一性に優れたメシル酸ペルゴリド含有製剤
HK1055678A (en) Sustained-release formulation of a cyclooxygenase-2 inhibitor

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication